Haemonetics (HAE) Q1 2027 Earnings: Vascular Closure and Persona PLUS Rollout Drive Operating Leverage
Executive Summary: Haemonetics’ Strong Start to Fiscal 2027 Haemonetics Corporation (NYSE: HAE) delivered a robust performance for the first quarter of fiscal 2027, driven by broad-based execution across its core business segments. The medical technology company demonstrated significant commercial momentum, prompting management to raise its full-year organic revenue growth guidance to a range of 4% … Read more









